Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986151 | 0.92 | MAPT (0.41) | MAOBMAOAKMT2AALDH1A1POLB | |
| SCHEMBL16746160 | 0.92 | MAOB (0.38) | MAOBMAOAKMT2AALDH1A1POLB | |
| SCHEMBL12242783 | 0.90 | HTT (0.43) | MAOBMAOAKMT2AALDH1A1POLB | |
| SCHEMBL11986129 | 0.90 | MAOB (0.37) | MAOBMAOAKMT2AALDH1A1POLB | |
| SCHEMBL16657456 | 0.89 | MAOB (0.40) | MAOBMAOAPOLBPARP10PARP14 | |
| SCHEMBL13828984 | 0.89 | POLB (0.45) | MAOBMAOAKMT2AALDH1A1POLB | |
| SCHEMBL13828884 | 0.88 | POLB (0.53) | MAOBMAOAKMT2APOLBAPEX1 | |
| SCHEMBL13829066 | 0.88 | POLB (0.50) | MAOBMAOAKMT2AALDH1A1POLB | |
| SCHEMBL11986117 | 0.87 | MAOB (0.36) | MAOBMAOAPOLBAPEX1HTT | |
| SCHEMBL11986088 | 0.87 | HIF1A (0.38) | MAOBMAOAPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505980-B2 | Polymerizable liquid crystal composition and optically anisotropic substance having twist alignment | JNC CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9399736-B2 | Optically anisotropic substance and liquid crystal display | JNC CORPORATION (JP) | 2016-07-26 | — | — | US | disclosed |
| US-20160011349-A1 | INFRARED REFLECTING FILM AND LAMINATED FILM | JNC PETROCHEMICAL CORPORATION (JP) | 2016-01-14 | — | — | US | disclosed |
| US-9150786-B2 | Polymerizable monomer compound, liquid crystal composition, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150146156-A1 | OPTICALLY ANISOTROPIC SUBSTANCE AND LIQUID CRYSTAL DISPLAY | JNC CORPORATION (JP) | 2015-05-28 | — | — | US | disclosed |
| US-20150108401-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND OPTICALLY ANISOTROPIC SUBSTANCE HAVING TWIST ALIGNMENT | JNC CORPORATION (JP) | 2015-04-23 | — | — | US | disclosed |
| US-20120286201-A1 | POLYMERIZABLE MONOMER COMPUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120286201-A1 | POLYMERIZABLE MONOMER COMPUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | MBD2, CCND1, MBTD1 | MAOB 3511/4885MAOA 4325/4885KMT2A 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.